Clinical Trials Logo

Clinical Trial Summary

The study is a phase 2, multi centered, single arm study designed to evaluate the correlation between cluster of differentiation 8-positive (CD8+) cell density and objective response rate in adults with unresected stage IIIB to IVM1c melanoma. This study will also evaluate the safety and tolerability profile of talimogene laherparepvec.


Clinical Trial Description

The study will explore the hypothesis that intratumoral CD8+ cell density at baseline correlates with objective response rate in adults with unresected stage IIIB to IVMIc melanoma treated with talimogene laherparepvec. ;


Study Design


Related Conditions & MeSH terms

  • Melanoma
  • Unresected Stage IIIb to IVM1c Melanoma

NCT number NCT02366195
Study type Interventional
Source Amgen
Contact
Status Completed
Phase Phase 2
Start date April 7, 2015
Completion date December 25, 2020

See also
  Status Clinical Trial Phase
No longer available NCT02147951 - Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma Phase 3
No longer available NCT02297529 - Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma